Top

Cordant CORE

Increase Your Visibility Into Prescription Adherence With Steady-State Oral Fluid Testing

Cordant CORE™ is the first patient-monitoring tool to use saliva samples to provide insights to providers if medication is present at a level consistent with the prescribed dosing regimen.  

Until CORE, most physicians were not able to distinguish between patients taking only some of their medication and patients taking their medications as prescribed, or if there are metabolic or health issues that need more investigation.

CORE is a breakthrough in the medication monitoring industry, as no other lab is able to determine from a non-invasive test, like saliva, if medication is present at the steady-state level consistent with the prescribed opioid treatment plan.

In comparison, traditional urine or saliva drug tests cannot provide this level of information or detail. They simply report the presence or absence of a drug, not if it is being taken consistently as prescribed or if there are metabolic issues occurring and more investigation is needed.
Richard Stripp, Ph.D.
Cordant Chief Scientific and Technical Officer

Data released from Cordant Health Solutions™ in 2018 illustrates the difference between traditional drug testing and CORE testing.*

From a traditional testing perspective, 80.9% of samples tested were classified as positive for the prescribed opioid, meaning the medication was present in the patient’s system at the time of collection.

However, when the same samples were tested using CORE, only 35.5% of patient results fell within the expected range, or at a level consistent with the prescribed dosing regimen. The other 44.9% of patients who tested as expected with the traditional test were found to be below (15.4%) or above (29.9%) their expected range using CORE.

TRADITIONAL TESTING

80.9% RESULTS AS EXPECTED FOR PRESCRIBED MEDICATIONS

CORDANT
CORE

35.5% RESULTS AS EXPECTED FOR PRESCRIBED MEDICATIONS

*Analysis of 4,248 CORE tests performed by Cordant nationwide; July 2015–Oct 2018

CORE In The News

A Novel Chronic Opioid Monitoring Tool to Assess Prescription Drug Steady State Levels in Oral Fluid (Peer-reviewed study on CORE)
New Oral Fluid Monitoring Test Could Help Reduce Drug Diversion, Safety
New Saliva Drug Test for Pain Patients
Play Video
Play Video

What Our Clients Are Saying

March 2017

CORE Launched

5000+

CORE Tests Performed

10,073,069 B2

U.S. Patent Number

September 2018

U.S. Patent Received

Please complete this form to request more information on CORE.